###begin article-title 0
###xml 12 17 <span type="species:ncbi:9606">human</span>
Growth of a human mammary tumor cell line is blocked by galangin, a naturally occurring bioflavonoid, and is accompanied by down-regulation of cyclins D3, E, and A
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 633 634 633 634 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 639 644 639 644 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high </sup>
###xml 130 135 <span type="species:ncbi:9606">human</span>
This study was designed to determine if and how a non-toxic, naturally occurring bioflavonoid, galangin, affects proliferation of human mammary tumor cells. Our previous studies demonstrated that, in other cell types, galangin is a potent inhibitor of the aryl hydrocarbon receptor (AhR), an environmental carcinogen-responsive transcription factor implicated in mammary tumor initiation and growth control. Because some current breast cancer therapeutics are ineffective in estrogen receptor (ER) negative tumors and since the AhR may be involved in breast cancer proliferation, the effects of galangin on the proliferation of an ER-, AhRhigh line, Hs578T, were studied.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 210 216 202 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FhAhRR</italic>
###xml 381 388 373 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGudLuc</italic>
###xml 456 457 448 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
AhR expression and function in the presence or absence of galangin, a second AhR inhibitor, alpha-naphthoflavone (alpha-NF), an AhR agonist, indole-3-carbinol, and a transfected AhR repressor-encoding plasmid (FhAhRR) were studied in Hs578T cells by western blotting for nuclear (for instance, constitutively activated) AhR and by transfection of an AhR-driven reporter construct, pGudLuc. The effects of these agents on cell proliferation were studied by 3H-thymidine incorporation and by flow cytometry. The effects on cyclins implicated in mammary tumorigenesis were evaluated by western blotting.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 239 246 235 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FhAhRR </italic>
###xml 461 464 457 460 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 524 525 519 520 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 527 529 522 524 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Hs578T cells were shown to express high levels of constitutively active AhR. Constitutive and environmental chemical-induced AhR activity was profoundly suppressed by galangin as was cell proliferation. However, the failure of alpha-NF or FhAhRR transfection to block proliferation indicated that galangin-mediated AhR inhibition was either insufficient or unrelated to its ability to significantly block cell proliferation at therapeutically relevant doses (IC50 = 11 muM). Galangin inhibited transition of cells from the G0/G1 to the S phases of cell growth, likely through the nearly total elimination of cyclin D3. Expression of cyclins A and E was also suppressed.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
Galangin is a strong inhibitor of Hs578T cell proliferation that likely mediates this effect through a relatively unique mechanism, suppression of cyclin D3, and not through the AhR. The results suggest that this non-toxic bioflavonoid may be useful as a chemotherapeutic, particularly in combination with agents that target other components of the tumor cell cycle and in situations where estrogen receptor-specific therapeutics are ineffective.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 330 331 330 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 372 373 372 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 556 557 556 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 584 585 584 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 634 635 634 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 636 637 636 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 295 301 <span type="species:ncbi:9606">humans</span>
Flavonoids are a diverse class of naturally occurring polyphenolic plant compounds that have a variety of therapeutically important biological activities. Several thousand plant flavonoids have been identified and biologically significant levels of bioflavonoids are consumed (about 1 g/day) by humans living in Western cultures [1]. Generally considered to be non-toxic [2], flavonoids have been touted as anti-inflammatory, anti-oxidant, chemopreventatives with the potential to be used for prevention or treatment of such diverse diseases as arthritis [3], cardiovascular disease [4], and several cancers, including breast cancer [5,6].
###end p 11
###begin p 12
###xml 149 168 149 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Alpinia officinarum</italic>
###xml 232 233 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 332 333 332 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 390 395 390 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">iNOS </italic>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 514 523 514 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 524 526 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 567 569 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 819 821 819 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 896 898 896 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 899 901 899 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 149 168 <span type="species:ncbi:199623">Alpinia officinarum</span>
###xml 321 330 <span type="species:ncbi:7460">honeybees</span>
###xml 605 611 <span type="species:ncbi:10090">murine</span>
Galangin (3,5,7-trihydroxyflavone) belongs to one class of flavonoids known as flavonols. It comprises approximately 10% of the ethanol extract from Alpinia officinarum, a plant used for many years in Asia as an herbal therapeutic [7], and is a major component of propolis, an anti-inflammatory composite gum produced by honeybees [8-10]. Among other biological activities, galangin blocks iNOS mRNA induction during inflammatory responses [11], down-regulates Cox-2 transcription [12], inhibits viral replication in vitro [13], and suppresses bacterial cell growth [14]. Recently, we generated data in a murine model of B lymphocyte development that suggest that galangin may further affect cellular biology through its interaction with an important receptor/transcription factor, the aryl hydrocarbon receptor (AhR) [15], implicated in spontaneous and carcinogen-induced mammary tumorigenesis [16-18].
###end p 12
###begin p 13
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 398 399 398 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 445 447 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 694 696 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 825 827 825 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 828 830 828 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 831 833 831 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 896 898 896 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 899 901 899 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
The AhR is a member of the Per/ARNT/Sim (PAS) family of transcription factors. PAS proteins have been shown to contribute to angiogenesis, neurological development, hypoxia responses, and circadian cycle [19-22]. The AhR is best known for its responsiveness to environmentally ubiquitous carcinogens such as polycyclic aromatic hydrocarbons (PAHs), dioxins (for example, 2,3,7,8 tetrachlorodibenzo-p-dioxin/TCDD), and polychlorinated biphenyls [23-25]. Once activated by these lipophilic pollutants, the AhR translocates to the nucleus where it binds to a second member of the PAS family, the aryl hydrocarbon nuclear translocator (ARNT), and to transcriptional co-activators or co-repressors [26-30]. The activated AhR complex then binds specific DNA recognition sequences and modulates transcription of a variety of genes [27,31,32]. Significantly, AhR activation can be blocked with galangin [15,33].
###end p 13
###begin p 14
###xml 80 85 80 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1 </italic>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 579 581 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
The most thoroughly characterized outcome of AhR activation is the induction of CYP1 genes encoding the cytochrome P-4501A1, 1A2, and 1B1 monooxygenases. These enzymes metabolize parent PAHs and polychlorinated biphenyls into mutagenic intermediates [34-39]. However, it is now becoming clear that the AhR, a highly conserved protein, plays an important role in cell cycle and apoptosis regulation in the absence of environmental chemicals [40-49]. Indeed, the potential role of the AhR in tumorigenesis has inspired the possible use of AhR modulators for breast cancer therapy [50].
###end p 14
###begin p 15
###xml 32 34 32 34 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 283 290 283 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 </italic>
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 838 840 838 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 1027 1029 1027 1029 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 164 169 <span type="species:ncbi:9606">human</span>
###xml 330 335 <span type="species:ncbi:9606">human</span>
###xml 414 419 <span type="species:ncbi:9606">human</span>
###xml 1029 1034 <span type="species:ncbi:9606">human</span>
Because it is an AhR inhibitor [15], it seemed plausible that galangin has the potential to block formation of mutagenic metabolites in tumor cells and to regulate human mammary cancer cell proliferation. The former possibility is supported by the demonstration that galangin blocks CYP1A1 induction and DNA-adduct formation in a human mammary tumor cell line [51]. The latter possibility, that galangin can alter human tumor cell proliferation after the transformation process has begun, was investigated herein. Particular emphasis was placed on the possibility that galangin mediates its presumptive growth regulatory effects through constitutively active tumor cell AhR and on the influence that galangin may have in altering levels of cyclins critical to maintenance of cell growth. Since at least some flavonoids are xenoestrogens [52], and since modulation of estrogen receptors (ERs) would be expected to affect cell proliferation, estrogen receptor modulation was eliminated as a confounder by performing studies on ER- human Hs578T tumor cells. Consequently, the results presented here have a bearing on the potential for galangin to be used as a chemotherapeutic in cases where ER-dependent therapeutics are either contraindicated or not effective because of ER loss.
###end p 15
###begin title 16
Materials and methods
###end title 16
###begin title 17
Reagents
###end title 17
###begin p 18
DMEM, RPMI, calcium- and magnesium-free PBS, L-glutamine, penicillin/streptomycin, trypsin-EDTA, and heat inactivated FCS were supplied by Invitrogen (Carlsbad, CA, USA). Galangin, indole-3-carbinol (I3C), and alpha-naphthoflavone (alpha-NF) were purchased from Aldrich Chemical Co. (Milwaukee, WI, USA) and dissolved in dimethylsulfoxide (99.9% high-performance liquid chromatography grade; Sigma Chemical Co., St Louis, MO, USA) at concentrations that were 1,000-fold higher than the desired final concentration. Insulin was obtained from Sigma.
###end p 18
###begin title 19
Cell culture
###end title 19
###begin p 20
###xml 6 8 6 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 356 358 349 351 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 15 20 <span type="species:ncbi:9606">human</span>
The ER- Hs578T human breast cancer epithelial cell line was purchased from the American Type Culture Collection (Manassas, VA, USA) and grown in DMEM (Sigma) supplemented with 10% FCS, 10 mug/ml insulin, 50 u/ml penicillin, 50 u/ml streptomycin, and 2 mM L-glutamine. Cells were maintained at subconfluency at 37degreesC in humidified air containing 10% CO2 by splitting cultures 1:4 every 3 to 4 days.
###end p 20
###begin title 21
###xml 1 2 1 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
[3H]-Thymidine incorporation
###end title 21
###begin p 22
###xml 26 27 26 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 147 148 146 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 261 264 260 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 269 272 268 271 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 410 411 405 406 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
Log phase Hs578T cells (103/well) were plated into 96-well tissue culture plates and allowed to adhere overnight. Cells were incubated with 1 muCi 3H-thymidine/well (NEN Life Science Products, Boston, MA, USA) in triplicate wells and dosed with 0.1% vehicle, 10-4 to 10-6 M galangin, I3C, or alpha-NF for 18 h. Cells were harvested onto filter mats using a PHD cell harvester (Brandel, Gaithersburg, MD, USA). 3H-thymidine retained on the filter was detected using a scintillation counter (Becton/Dickinson, San Jose, CA, USA). Triplicates for each data point in each experiment were averaged to give an 'n' of one.
###end p 22
###begin title 23
Transient transfections and reporter assays
###end title 23
###begin p 24
###xml 4 31 4 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fundulus heteroclitus AhRR </italic>
###xml 50 52 50 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 267 277 267 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGudLuc6.1</italic>
###xml 317 324 317 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGudLuc</italic>
###xml 494 501 494 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 </italic>
###xml 511 513 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 4 25 <span type="species:ncbi:8078">Fundulus heteroclitus</span>
###xml 224 229 <span type="species:ncbi:9606">human</span>
###xml 234 240 <span type="species:ncbi:10090">murine</span>
The Fundulus heteroclitus AhRR expression vector [53] was generously provided by Dr M Hahn and Dr S Karchner (Woods Hole Oceanographic Institution). We and others have shown that this construct is a potent inhibitor of both human and murine AhR activity [53,54]. The pGudLuc6.1-firefly luciferase reporter construct (pGudLuc) was kindly provided by Dr M Denison (UC Davis). AhR-dependent expression of this reporter is driven by four aryl hydrocarbon response elements (AhREs) derived from the CYP1A1 promoter [55].
###end p 24
###begin p 25
###xml 16 17 16 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 256 264 256 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">phRL-TK </italic>
###xml 331 335 329 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGL3</italic>
###xml 345 353 343 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGudLuc </italic>
###xml 400 413 397 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pcDNA-FhAhRR </italic>
###xml 424 430 421 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pcDNA </italic>
Hs578T cells (105/well) were seeded into 6-well culture plates and grown to 70% to 80% confluence. Lipofectamine 2000 transfection reagent (Invitrogen) was used according to the manufacturer's instructions to transfect cells. The renilla luciferase vector phRL-TK (0.5 mug/well) was co-transfected with the 0.1 mug control vector (pGL3) or with pGudLuc per well. Where indicated, 0.125 to 0.5 mug of pcDNA-FhAhRR or control pcDNA were added with or without the reporter construct to the transfection mixture. For each experiment, the amount of total DNA transfected was equilibrated with parental expression vectors. Cells were incubated for 18 hours, washed twice with PBS (pH 7.2), and resuspended in 75 mul RPMI prior to luciferase assays. Luciferase activity was determined with the Dual Glo Luciferase system (Promega, Madison, WI, USA), allowing sequential reading of the firefly and renilla signals. Briefly, cells were lysed in equal volumes of cell lysis buffer (Promega) and RPMI for 20 minutes, transferred to a 96-well white wall plate, and analyzed using a Reporter Luminometer (Promega). The renilla signal was read after quenching the firefly output, thus allowing normalization between sample wells.
###end p 25
###begin p 26
###xml 62 69 62 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FhAhRR </italic>
###xml 80 86 80 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pcDNA </italic>
###xml 157 159 157 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 286 287 285 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 365 366 364 365 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
For experiments in which cell proliferation was assayed after FhAhRR or control pcDNA transfection, transfected cells were resuspended in RPMI and plated (103 cells/well) into 96-well tissue culture plates in triplicate and allowed to adhere overnight. Cells were incubated with 1 muCi 3H-thymidine/well (NEN Life Science Products) and triplicate wells assayed for 3H-thymidine incorporation as described above. Results in the triplicates were averaged for each data point in each experiment.
###end p 26
###begin title 27
Cell cycle and apoptosis analyses by flow cytometry
###end title 27
###begin p 28
###xml 16 17 16 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 350 351 350 351 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 353 354 353 354 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
Hs578T cells (105/well) were seeded into 6-well tissue culture plates and allowed to adhere overnight. Growth arrest was achieved by washing the cells three times with cold PBS before adding supplemented DMEM containing no FCS. In preliminary experiments it was determined that 48 hours without FCS was required to arrest 80% to 90% of the cells in G0/G1. Less than 5% of these cells stained with trypan blue, indicating a high level of viability. Cells were rescued from growth arrest by adding FCS to culture wells (10% final concentration) with 0.1% vehicle, galangin, I3C, or alpha-NF. Cells were harvested 24 hours later and analyzed for cell cycle as described below.
###end p 28
###begin p 29
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 257 263 <span type="species:ncbi:9913">bovine</span>
Cell cycle analyses and apoptosis quantification were performed by staining cellular DNA with propidium iodide (PI) in permeabilized cells as we have previously described [56-58]. Cells were trypsinized, pelleted, and washed in cold PBS containing 5% fetal bovine serum and 0.02 M sodium azide. Cells were centrifuged for 5 minutes at 1,000 rpm at 4degreesC and resuspended in 0.3 ml hypotonic buffer containing 50 mug/ml PI (Sigma), 1% sodium citrate, and 0.1% Triton X-100 and stored protected from light until analysis. Flow cytometry was performed on a Becton/Dickinson FACScan flow cytometer. Data (5,000 events) were collected on both linear and log scales to assess cell cycle and apoptosis, respectively.
###end p 29
###begin title 30
Western immunoblotting
###end title 30
###begin p 31
###xml 53 55 53 55 <sub xmlns:xlink="http://www.w3.org/1999/xlink">10</sub>
###xml 904 910 <span type="species:ncbi:9986">rabbit</span>
###xml 969 974 <span type="species:ncbi:10090">mouse</span>
###xml 1026 1032 <span type="species:ncbi:9986">rabbit</span>
###xml 1049 1055 <span type="species:ncbi:9986">rabbit</span>
###xml 1075 1081 <span type="species:ncbi:9986">rabbit</span>
###xml 1234 1238 <span type="species:ncbi:9925">goat</span>
###xml 1244 1250 <span type="species:ncbi:9986">rabbit</span>
###xml 1255 1266 <span type="species:ncbi:3704">horseradish</span>
###xml 1320 1324 <span type="species:ncbi:9925">goat</span>
###xml 1330 1335 <span type="species:ncbi:10090">mouse</span>
###xml 1340 1351 <span type="species:ncbi:3704">horseradish</span>
Cells were scraped into cold PBS and resuspended in P10EG lysis buffer containing 10 mM sodium phosphate, 0.75 mM EDTA, 10% glycerol, 0.125% Triton X-100 and 1.0% protease inhibitor cocktail (Sigma). Cells were lysed after 50 strokes in a Dounce tissue homogenizer (Bellco Glass, Vineland, NJ, USA) and lysis was confirmed by light microscopy. After 15 minutes on ice, cells were centrifuged for 15 minutes at 13,000 rpm at 4degreesC. Supernatants were removed and stored at -80degreesC until western analysis. Proteins (30 mug/sample) were electrophoresed through 10% SDS-polyacrylamide gels for 1.5 hours at 100 V. Proteins then were transferred to nitrocellulose membranes and membranes blocked for 1 hour at room temperature with 5% non-fat dry milk in PBS with 0.5% Tween-20 (PBS-T). Membranes were probed with the following primary antibodies diluted 1:200 in PBS-T containing 5% non-fat dry milk: rabbit anti-AhR (Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse anti-cyclin A (BD Pharmingen, San Diego, CA, USA), rabbit anti-cyclin D1, rabbit anti-cyclin D3, or rabbit anti-cyclin E (Santa Cruz Biotechnology). Membranes were washed 4 times for 5 minutes each with PBS-T and incubated for 1 hour at room temperature with goat anti-rabbit IgG horseradish peroxidase conjugate (Bio-Rad, Hercules, CA, USA) or goat anti-mouse IgG horseradish peroxidase conjugate (Sigma) at a dilution of 1:20,000 or 1:5,000, respectively, prepared in PBS-T containing 5% non-fat dry milk. Membranes were washed extensively with PBS-T and developed with enhanced chemiluminescence. Blots were reprobed up to three times with a different primary antibody after treating for 15 minutes with stripping solution (Chemicon, Temecula, CA, USA) and incubating twice for 5 minutes with blocking solution (Chemicon).
###end p 31
###begin title 32
Image analyses
###end title 32
###begin p 33
Image analyses were performed on western immunoblotting autoradiographs that were digitally scanned using a Cytocore, Inc. (Chicago, IL, USA) densitometer. To compare relative band densities between immunoblots, all bands were normalized using beta-actin band densities.
###end p 33
###begin title 34
Statistical analyses
###end title 34
###begin p 35
###xml 375 384 375 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">post hoc </italic>
Statistical analyses were performed with Statview (SAS Institute, Cary, NC, USA). Data from triplicate samples were averaged for each data point for an 'n' of one in each experiment. Data from a minimum of three experiments are presented as means + standard errors (SE). One-factor ANOVAs were used to analyze the data. A Fisher PLSD (protected least significant difference) post hoc comparisons test was used to determine significant differences.
###end p 35
###begin title 36
Results
###end title 36
###begin title 37
Galangin represses constitutive and ligand-induced AhR transcriptional activity
###end title 37
###begin p 38
###xml 85 87 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 308 310 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 311 313 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 60 65 <span type="species:ncbi:9606">human</span>
###xml 70 76 <span type="species:ncbi:10090">murine</span>
###xml 199 204 <span type="species:ncbi:9606">human</span>
###xml 428 433 <span type="species:ncbi:9606">human</span>
###xml 583 588 <span type="species:ncbi:9606">human</span>
The AhR is expressed at high levels in many rapidly growing human and murine tumors [16,33,40-46,50,59,60]. More specifically, high levels of both cytoplasmic and nuclear AhR characterize rodent and human tumors, including mammary tumors induced with an AhR ligand [16,43,59,61]. These and other results [59,62,63] suggest that the AhR is constitutively active in rapidly growing transformed cells. To extend these studies to a human tumor model in which the effects of AhR inhibitors such as galangin can be studied, AhR expression and subcellular localization were determined in a human mammary tumor cell line, Hs578T.
###end p 38
###begin p 39
###xml 28 36 28 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 37 39 37 39 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 151 152 151 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
As seen with primary tumors in vivo [16], significant levels of AhR protein were detected in both the cytoplasm and the nuclei of Hs578T cells (Figure 1), a result consistent with constitutive AhR activity in this line. The presence of the AhR in this cell line is consistent with a previous report from Wang and colleagues [64] in which binding of a functional AhR to its cognate DNA response element was demonstrated after agonist treatment.
###end p 39
###begin p 40
###xml 153 160 153 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGudLuc</italic>
###xml 469 477 469 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">phRL-TK </italic>
###xml 533 538 533 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGL3 </italic>
###xml 549 557 549 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGudLuc </italic>
If this nuclear AhR were indeed constitutively active, it would be predicted that transient transfection of an AhR-driven luciferase reporter construct (pGudLuc) would result in significant levels of background transcriptional activity and that this activity would be inducible with AhR ligands and inhibitable with AhR competitive inhibitors, including galangin. To test these predictions, Hs578T cells were transiently transfected with the renilla luciferase plasmid phRL-TK to control for transfection efficiency and with control pGL3 plasmid or pGudLuc plasmid and treated with vehicle, one of two AhR inhibitors (galangin, alpha-NF), or an AhR agonist (I3C). Renilla and firefly luciferase activities were assayed 18 hours later.
###end p 40
###begin p 41
###xml 32 40 32 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGudLuc </italic>
###xml 115 119 115 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGL3</italic>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 198 201 198 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 276 277 276 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 306 309 306 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5 </sup>
###xml 448 449 448 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 495 498 491 494 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 542 544 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 545 547 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 581 589 577 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGudLuc </italic>
###xml 599 600 595 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 645 647 641 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 693 701 689 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGudLuc </italic>
As predicted, transfection with pGudLuc increased normalized luciferase activity approximately 50-fold relative to pGL3-transfected controls in this series of experiments (Figure 2a). Addition of 10-4 M galangin completely blocked the constitutive level of reporter activity (p < 0.02). At a lower dose (10-5 M), galangin tended to decrease the activity, although the data did not reach statistical significance in the three experiments performed (p = 0.056). A synthetic flavonoid, alpha-NF (10-6 M), previously shown to block AhR activity [65,66], similarly reduced constitutive pGudLuc activity (p < 0.02). As expected from previous studies [50], I3C, an AhR agonist, significantly induced pGudLuc reporter levels.
###end p 41
###begin p 42
###xml 64 67 64 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-9 </sup>
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 147 155 147 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGudLuc </italic>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 261 264 261 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 269 272 269 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5 </sup>
###xml 288 291 288 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 340 341 336 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 413 421 409 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGudLuc </italic>
###xml 574 579 <span type="species:ncbi:9606">human</span>
A similar profile was seen when AhR activity was induced with 10-9 M TCDD (Figure 2b). That is, TCDD significantly increased the baseline level of pGudLuc activity (Figure 2b, first histogram) relative to untreated controls (Figure 2a, first histogram) while 10-4 to 10-5 M galangin or 10-6 M alpha-NF significantly blocked this induction (p < 0.02). I3C, together with TCDD, resulted in the greatest increase in pGudLuc activity. These data demonstrate that both galangin and alpha-NF can suppress constitutive and TCDD-induced, AhR-dependent transcriptional activity in a human mammary tumor cell line.
###end p 42
###begin title 43
Galangin inhibits Hs578T cell proliferation
###end title 43
###begin p 44
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 101 104 101 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 109 112 109 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 208 211 204 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 491 494 479 482 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 499 502 487 490 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5 </sup>
###xml 528 529 516 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 580 581 568 569 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 615 617 603 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 625 628 613 616 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 648 649 636 637 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 771 774 759 762 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 862 864 849 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 972 974 959 961 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1024 1026 1010 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 1067 1069 1053 1055 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1076 1078 1062 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1079 1081 1065 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 1082 1084 1068 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 1113 1114 1099 1100 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 1257 1258 1239 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
Since molecular manipulation of AhR activity can affect cell proliferation [40,44], the ability of 10-4 to 10-6 M galangin, alpha-NF, and I3C to alter Hs578T cell growth was studied. At the highest dose of 10-4 M, alpha-NF was toxic (>50% dead as measured by PI staining) and was not assessed further at that dose for its ability to inhibit proliferation. No toxicity was observed with the other compounds at any dose or with alpha-NF at lower doses (<3% dead by PI staining). Addition of 10-4 to 10-5 M galangin significantly (p < 0.04) reduced cell proliferation as measured by 3H-thymidine incorporation (Figure 3a). At 10-6 M, galangin reduced 3H-thymidine incorporation by approximately 25%, although this reduction was not statistically significant. Overall, the IC50 (median inhibition concentration) of galangin under these conditions was 11 muM (Figure 3b), a result that compares favorably with concentrations of tamoxifen required to inhibit proliferation of ER+ mammary tumor cells by 50% (for example, 31 muM) [67]. Consistent with previous studies in ER+ cells [18,68,69], I3C significantly reduced 3H-thymidine incorporation at all doses tested. Interestingly, alpha-NF, which was shown to be a potent AhR inhibitor in this cell line (Figure 2), had no effect on Hs578T cell proliferation.
###end p 44
###begin p 45
###xml 470 472 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 621 623 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 624 626 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 627 629 623 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 686 693 682 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 </italic>
###xml 830 832 826 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 833 835 829 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 876 891 872 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. heteroclitus</italic>
###xml 980 982 976 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 1003 1024 999 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. heteroclitus AhRR </italic>
###xml 1025 1031 1021 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FhAhRR</italic>
###xml 1085 1093 1081 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGudLuc </italic>
###xml 1131 1136 1127 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AhRR </italic>
###xml 1185 1192 1181 1188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FhAhRR </italic>
###xml 865 874 <span type="species:ncbi:8078">killifish</span>
###xml 876 891 <span type="species:ncbi:8078">F. heteroclitus</span>
###xml 907 912 <span type="species:ncbi:9606">human</span>
###xml 917 922 <span type="species:ncbi:10090">mouse</span>
###xml 1003 1018 <span type="species:ncbi:8078">F. heteroclitus</span>
###xml 1125 1130 <span type="species:ncbi:9606">human</span>
The ability of both an AhR antagonist (galangin) and an AhR agonist (I3C) to suppress cell proliferation, and the failure of a second AhR antagonist (alpha-NF) to affect proliferation, suggested that AhR down-regulation is either not involved or is insufficient for galangin-dependent proliferation inhibition. Since pharmacological agents such as galangin and I3C may have multiple biological activities, a second approach, transfection with an AhR-specific repressor [53], was taken to confirm that AhR down-regulation in and of itself is not sufficient to alter Hs578T cell proliferation. An evolutionarily conserved [53,70-73] AhR repressor (AhRR) specifically blocks AhR-dependent CYP1A1 activity by competing for the AhR binding partner ARNT and by blocking binding of this complex to recognition sequences in target genes [53,70]. Notably, AhRR derived from killifish (F. heteroclitus) inhibits both human and mouse AhR-dependent transactivation in an AhR-specific manner [53]. In our hands, the F. heteroclitus AhRR (FhAhRR) expression plasmid is more effective at suppressing pGudLuc activity in Hs578T cells than a human AhRR expression construct (not shown). Therefore, the FhAhRR construct was used to determine if inhibition of AhR activity is sufficient to suppress Hs578T cell proliferation.
###end p 45
###begin p 46
###xml 47 54 47 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FhAhRR </italic>
###xml 65 71 65 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pcDNA </italic>
###xml 83 90 83 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGudLuc</italic>
###xml 103 110 103 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FhAhRR </italic>
###xml 131 139 131 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGudLuc </italic>
###xml 189 196 189 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FhAhRR </italic>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 287 295 287 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGudLuc </italic>
###xml 424 431 424 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FhAhRR </italic>
###xml 461 462 461 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 496 497 496 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
Hs578T cells were transiently transfected with FhAhRR or control pcDNA either with pGudLuc, to confirm FhAhRR activity, or without pGudLuc to evaluate cell proliferation. Transfection with FhAhRR significantly reduced both the constitutive (Figure 4a) and the TCDD-inducible (Figure 4b) pGudLuc reporter activity in transfected Hs578T cells, confirming the potent inhibitory activity of ectopically expressed AhRR. However, FhAhRR transfection had no effect on 3H-thymidine incorporation (Figure 5). These results demonstrate that AhR repression is not sufficient to effect inhibition of proliferation in this cell line. It is concluded that galangin's ability to inhibit cell proliferation either doesn't involve the AhR or is mediated by AhR suppression together with other activities.
###end p 46
###begin title 47
###xml 17 18 17 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 20 22 20 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Galangin blocks G0/G1 to S transition
###end title 47
###begin p 48
###xml 367 368 363 364 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 370 372 366 368 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 419 423 415 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6a,b</xref>
###xml 487 488 483 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 531 532 527 528 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 534 536 530 532 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 664 665 660 661 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 667 669 663 665 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 718 719 714 715 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 721 723 717 719 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 784 787 780 783 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 939 940 935 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 945 948 941 944 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5 </sup>
###xml 953 956 949 952 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 1013 1014 1005 1006 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 1016 1018 1008 1010 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1045 1046 1037 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 1073 1076 1065 1068 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 1108 1109 1100 1101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1158 1159 1150 1151 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 1161 1163 1153 1155 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
To determine the stage(s) of cell cycle at which galangin blocks proliferation, Hs578T cells were synchronized by serum deprivation for 48 hours and then serum rescued in the presence of galangin, alpha-NF, or I3C. DNA content was assayed 24 hours after serum rescue by PI staining and flow cytometry. Approximately 60% of the cells growing in log phase were in the G0/G1 phase of cell growth at any given time (Figure 6a,b). Growth arrest induced by deprivation of serum significantly (p < 0.01) increased the number of cells in G0/G1 to approximately 80%. Addition of serum with vehicle initiated cell cycle as indicated by a decrease in the number of cells in G0/G1 to approximately 25%. However, this decrease in G0/G1 cells was not seen when serum was added in the presence of 10-4 M galangin. One log less galangin had no effect on serum rescue. As expected from its failure to affect proliferation of non-synchronized cells (Figure 3), 10-5 to 10-6 M alpha-NF had no effect on the number of cells exiting G0/G1 after serum rescue (Figure 6). The highest I3C dose (10-4 M) partially but significantly (p < 0.01) inhibited transition of cells from the G0/G1 into the S phase of cell cycle after serum rescue. Again, since I3C and its metabolites have multiple biological activities, we cannot conclude that the effect seen in H3578T cells is due to its AhR agonist activity.
###end p 48
###begin p 49
###xml 130 131 130 131 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 133 135 133 135 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6b</xref>
###xml 428 429 428 429 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 431 433 431 433 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Growth-arrested, serum-rescued, and flavonoid-treated cells also were assayed for apoptosis as measured by the presence of a sub G0/G1 peak as we have described [56-58]. Regardless of treatment, less than 8% of the cells were apoptotic and no differences were seen between groups at doses shown in Figure 6b (not shown). These data indicate that galangin is non-toxic and that it blocks the transition of Hs578T cells from the G0/G1 to the S phase of cell growth.
###end p 49
###begin title 50
Galangin down-regulates cyclins D3, E, and A
###end title 50
###begin p 51
###xml 184 185 184 185 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 187 189 187 189 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B74">74</xref>
###xml 357 359 357 359 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 419 421 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B75">75</xref>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B76">76</xref>
###xml 581 583 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B77">77</xref>
###xml 584 586 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B79">79</xref>
###xml 718 721 718 721 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 741 744 741 744 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 756 759 756 759 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5 </sup>
Cell cyclins tightly regulate the transition of cells through the phases of the cell cycle. The D cyclins are upregulated at the initiation of the cell cycle and drive cells from the G0/G1 to the S phase of growth in part through retinal blastoma protein (Rb) phosphorylation [74]. Cyclin E is upregulated by E2F released from Rb during the late phases of G1 and, once in complex with Cdk2, commits the cell to divide [75]. Cyclin A functions both in the S and M phases of the cell cycle [76]. Dysregulation of each of these cyclins has been associated with mammary tumorigenesis [77-79]. To determine at what level(s) galangin effects proliferation inhibition, Hs578T cells were left untreated or were treated with 10-4 M galangin, 2.5 x 10-4 M I3C, or 10-5 M alpha-NF and assayed for cyclin D1, D3, E, and A expression 18 hours thereafter.
###end p 51
###begin p 52
###xml 151 155 151 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7a,b</xref>
###xml 311 312 311 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 329 330 329 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 455 456 455 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 551 552 551 552 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 554 556 554 556 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Although galangin tended to decrease cyclin D1 expression, the data did not reach statistical significance in this series of three experiments (Figure 7a,b). However, expression of cyclin D3 was nearly undetectable in galangin-treated cells. Furthermore, galangin significantly reduced expression of cyclins A (p < 0.001) and E (p < 0.02). Since cyclins A and E function downstream of cyclin D3, these data are consistent with the cell cycle data (Figure 6) and support, but do not prove, the hypothesis that galangin blocks transition of cells from G0/G1 into S phase by profoundly down-regulating at least cyclin D3. As in previous experiments, no overt toxicity (for instance, uptake of trypan blue) was noted following galangin treatment (data not shown).
###end p 52
###begin p 53
###xml 155 159 151 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7a,b</xref>
###xml 287 288 283 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
In contrast, neither I3C nor alpha-NF significantly affected expression of the cyclins assayed herein, even though relatively high doses were used (Figure 7a,b). The failure of I3C to inhibit expression of these cyclins, while clearly affecting cell proliferation at lower doses (Figure 3), suggests its ability to interfere with components of the cell cycle machinery not assayed here and distinct from those targeted by galangin.
###end p 53
###begin title 54
Discussion
###end title 54
###begin p 55
###xml 304 305 304 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 497 499 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 789 792 789 792 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
In the search for less toxic breast cancer chemotherapeutics, many laboratories have turned their attention to naturally occurring bioflavonoids or synthetic analogues thereof. Galangin is one such polyphenolic compound that has been shown to have significant biological activity in a number of systems [7-11,13]. In our hands, galangin is a potent inhibitor of environmental chemical toxicity mediated by carcinogenic polycyclic aromatic hydrocarbons through its ability to block AhR activation [15]. In those studies, galangin inhibited AhR activation without overt toxicity to what would otherwise be considered extremely sensitive cells, that is, developing bone marrow hematopoietic cells. The lack of toxicity is supported further by the present studies, in which doses as high as 10-4 M failed to induce overt cell death, as measured by trypan blue uptake, or more cryptic apoptotic death, as measured by a decrease in staining with PI in permeabilized cells.
###end p 55
###begin p 56
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B80">80</xref>
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 219 221 219 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B81">81</xref>
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B84">84</xref>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 432 433 432 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 612 620 612 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGudLuc </italic>
###xml 691 692 687 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 698 705 694 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FhAhRR </italic>
###xml 726 727 722 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 1117 1119 1113 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1195 1197 1191 1193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 405 410 <span type="species:ncbi:9606">human</span>
###xml 456 461 <span type="species:ncbi:9606">human</span>
###xml 1095 1100 <span type="species:ncbi:9606">human</span>
A number of studies demonstrated that the AhR can regulate cell proliferation [42,80]. In several cases, particularly with regard to rapidly growing or transformed cells, the AhR appears to be constitutively active [44,63,81-84]. Our laboratory has shown that this phenomenon holds for rodent mammary tumors induced with prototypic AhR ligands [16]. Similarly, high levels of nuclear AhR were observed in human Hs578T cells (Figure 1) and in several other human breast cancer cell lines (for example, CAMA-1, MCF-7, and MDA MB 231; data not shown). In addition, the presence of a significant background level of pGudLuc reporter activity that was inhibitable with galangin, alpha-NF (Figure 2), or FhAhRR transfection (Figure 4), indicated that the AhR is constitutively active in Hs578T cells. Therefore, it is reasonable to hypothesize that AhR up-regulation is a general characteristic of mammary tumors and that it influences their growth. In support of this hypothesis, AhR inhibition through molecular manipulations, such as transfection of AhR-specific siRNA, suppresses proliferation of human hepatoma cells [40] while AhR-defective hepatoma cells grow more slowly than wild-type cells [44].
###end p 56
###begin p 57
###xml 224 225 224 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 268 269 268 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 274 275 274 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 284 287 284 287 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 373 375 372 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 396 398 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 460 467 454 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FhAhRR </italic>
###xml 1032 1038 1026 1032 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FhAhRR</italic>
Because of these results, we had initially proposed that galangin would effect a change in mammary tumor cell proliferation through inhibition of AhR activity. Indeed, galangin was shown to both inhibit AhR activity (Figure 2) and to block cell proliferation (Figures 3 and 6). The IC50 of galangin (11 muM) in this system was similar to that reported for tamoxifen with ER+ MCF-7 cells (31 muM)[67]. However, cell proliferation was not altered by alpha-NF or FhAhRR despite their ability to suppress AhR activity as efficiently as galangin. Therefore, it appears either that the AhR is not involved in suppressing proliferation or that AhR inhibition is not sufficient to block proliferation of this relatively advanced tumor cell line. This result does not rule out the possibility that AhR down-regulation is sufficient to alter proliferation of less aggressive mammary tumors. Indeed, recent experiments demonstrate that inhibition of AhR activity in pre-malignant, MCF-10F mammary epithelial cells through transduction with an FhAhRR-containing lentivirus vector profoundly inhibits proliferation (data not shown).
###end p 57
###begin p 58
###xml 115 123 115 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGudLuc </italic>
###xml 214 219 214 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1 </italic>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 579 584 579 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1 </italic>
###xml 658 660 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 703 704 703 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
Furthermore, the demonstration that galangin dramatically inhibits constitutive and environmental chemical-induced pGudLuc activity is an important observation in and of itself. Active AhR induces transcription of CYP1 genes encoding enzymes that biotransform ubiquitous environmental carcinogens (for example, PAH) and putative endogenous substrates [63] into mutagenic metabolites. Consequently, non-toxic flavonoids such as galangin may be seen as potential chemopreventatives capable of blocking mutation-driven tumor initiation and/or progression through down-regulation of CYP1 transcription. Its ability also to block CYP1A1 enzyme activity directly [51], and to act as a free radical scavenger [2], suggests two additional levels at which galangin may restrict mutagen production or activity.
###end p 58
###begin p 59
###xml 111 112 111 112 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 114 116 114 116 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 388 390 388 390 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 514 516 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B85">85</xref>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B86">86</xref>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B85">85</xref>
###xml 831 833 831 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B85">85</xref>
###xml 834 836 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B87">87</xref>
###xml 1015 1017 1015 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B88">88</xref>
Flow cytometric studies presented herein demonstrate that galangin blocks transition of Hs578T cells from the G0/G1 into S phase of cell growth. Profound inhibition of cyclin D3 expression and the tendency to reduce cyclin D1 expression after galangin exposure are consistent with this finding since activation of cyclin D-CDK4 complexes is rate limiting in transition of cells from the G1 to S phase of cell growth. These observations are important since cyclin D3 plays a critical role in mammary tumorigenesis [85,86] but has not yet been specifically targeted with chemotherapeutics. Interestingly, it has been suggested that cyclin D3 preferentially promotes development of squamous carcinomas [85] and that it activates an oncogenic pathway in mammary epithelial cells that is distinct from the pathway induced by cyclin D1 [85,87]. Consequently, the preferential down-regulation of cyclin D3 by galangin may complement and increase the inhibitory effects of putative chemotherapeutics that target cyclin D1 [88] or, for that matter, other components that regulate cell cycle in tumors.
###end p 59
###begin p 60
###xml 268 269 268 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
Since transcription of cyclins E and A is regulated by the D cyclins through control of Rb phosphorylation and E2F release, it is likely that cyclin D3 down-regulation is responsible for the observed decreases in cyclins E and A seen in galangin-treated cells (Figure 7). Experiments now underway are testing this and the alternative possibility, that galangin directly suppresses cyclins E and A as well as cyclin D3. In either case, the down-regulation of multiple cyclins known to be involved in mammary tumorigenesis emphasizes the potential for galangin to serve as an effective inhibitor of mammary tumor proliferation.
###end p 60
###begin title 61
Conclusion
###end title 61
###begin p 62
###xml 143 145 143 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 581 583 581 583 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
We have described the novel finding that a naturally occurring, non-toxic bioflavonoid, galangin, effectively suppresses proliferation of an ER- cell line. This proliferation inhibition is accompanied by down-regulation of cyclins D3, E, and A. While galangin inhibits the activity of the AhR, a transcription factor implicated in the initiation and growth of mammary tumors, AhR inhibition was either not required or not sufficient to suppress proliferation of this cell line. These results suggest that this bioflavonoid may represent a useful therapeutic for the treatment of ER- mammary tumors and should complement the effects of therapeutics that target other dysregulated components of the cell cycle machinery.
###end p 62
###begin title 63
Abbreviations
###end title 63
###begin p 64
###xml 430 431 422 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 244 248 <span type="species:ncbi:9913">calf</span>
alpha-NF = alpha-naphthoflavone; AhR = aryl hydrocarbon receptor; AhRR = aryl hydrocarbon receptor repressor; ARNT = aryl hydrocarbon receptor nuclear translocator; DMEM = Dulbecco's modified Eagle's medium; ER = estrogen receptor; FCS = fetal calf serum; I3C = indole 3-carbinol; PAH = polycyclic aromatic hydrocarbon; PAS = Per/ARNT/Sim; PBS = phosphate-buffered saline; PI = propidium iodide; TCDD = 2,3,7,8-tetrachlorodibenzo-p-dioxin.
###end p 64
###begin title 65
Competing interests
###end title 65
###begin p 66
The authors declare that they have no competing interests.
###end p 66
###begin title 67
Authors' contributions
###end title 67
###begin p 68
###xml 15 16 15 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
TJM performed [3H]-thymidine incorporation experiments, cell cycle and apoptosis analyses, and western immunoblotting, participated in the experimental design and coordination of this project, and participated in writing the manuscript. XY performed transient transfections and reporter assays and western immunoblotting, participated in the experimental design and coordination of the project, and contributed to the writing of the manuscript. DHS conceived of the experimental design, performed statistical analyses, and prepared the manuscript. All authors approved the final manuscript.
###end p 68
###begin title 69
Acknowledgements
###end title 69
###begin p 70
This work was supported by Grants PO1 ES11624, PO1-HL68705, RO1-ES06086, and P42-ES07381.
###end p 70
###begin article-title 71
Review of the biology of quercetin and related bioflavonoids
###end article-title 71
###begin article-title 72
Anti-genotoxicity of galangin as a cancer chemopreventive agent candidate
###end article-title 72
###begin article-title 73
Comparative study of flavonoids in experimental models of inflammation
###end article-title 73
###begin article-title 74
###xml 78 83 <span type="species:ncbi:9606">women</span>
Dietary flavonoid intake and risk of cardiovascular disease in postmenopausal women
###end article-title 74
###begin article-title 75
Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation
###end article-title 75
###begin article-title 76
Natural inhibitors of carcinogenesis
###end article-title 76
###begin article-title 77
###xml 61 80 <span type="species:ncbi:199623">Alpinia officinarum</span>
Presence of fatty acid synthase inhibitors in the rhizome of Alpinia officinarum hance
###end article-title 77
###begin article-title 78
Separation of flavonoids and phenolic acids from propolis by capillary zone electrophoresis
###end article-title 78
###begin article-title 79
Phytochemical compounds involved in the anti-inflammatory effect of propolis extract
###end article-title 79
###begin article-title 80
###xml 64 69 <span type="species:ncbi:9606">human</span>
Inhibition of proliferation of estrogen receptor-positive MCF-7 human breast cancer cells by flavonoids in the presence and absence of excess estrogen
###end article-title 80
###begin article-title 81
Effects of ethanol extract of propolis (EEP) and its flavones on inducible gene expression in J774A.1 macrophages
###end article-title 81
###begin article-title 82
Effect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcription
###end article-title 82
###begin article-title 83
###xml 53 80 <span type="species:ncbi:10298">herpes simplex virus type 1</span>
Synergistic effect of flavones and flavonols against herpes simplex virus type 1 in cell culture. Comparison with the antiviral activity of propolis
###end article-title 83
###begin article-title 84
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
###xml 38 60 <span type="species:ncbi:1314">Streptococcus pyogenes</span>
In vitro activity of propolis against Streptococcus pyogenes
###end article-title 84
###begin article-title 85
The bioflavonoid galangin blocks aryl hydrocarbon receptor (AhR) activation and polycyclic aromatic hydrocarbon-induced pre-B cell apoptosis
###end article-title 85
###begin article-title 86
###xml 89 94 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1 </italic>
###xml 118 121 <span type="species:ncbi:10116">rat</span>
Expression of the aryl hydrocarbon receptor/transcription factor (AhR) and AhR-regulated CYP1 gene transcription in a rat model of mammary tumorigenesis
###end article-title 86
###begin article-title 87
###xml 19 26 19 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 56 59 <span type="species:ncbi:10116">rat</span>
Identification and in vivo formation of 32P-postlabeled rat mammary DMBA - DNA adducts
###end article-title 87
###begin article-title 88
###xml 53 56 <span type="species:ncbi:10116">rat</span>
Inhibition of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor growth by aryl hydrocarbon receptor agonists
###end article-title 88
###begin article-title 89
The PAS superfamily: sensors of environmental and developmental signals
###end article-title 89
###begin article-title 90
Identification of the downstream targets of SIM1 and ARNT2, a pair of transcription factors essential for neuroendocrine cell differentiation
###end article-title 90
###begin article-title 91
Cross-talk between the aryl hydrocarbon receptor and hypoxia inducible factor signaling pathways. Demonstration of competition and compensation
###end article-title 91
###begin article-title 92
###xml 73 77 <span type="species:ncbi:10090">mice</span>
Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT
###end article-title 92
###begin article-title 93
###xml 49 52 49 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ah </italic>
Characterization of polyclonal antibodies to the Ah receptor prepared by immunization with a synthetic peptide hapten
###end article-title 93
###begin article-title 94
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
In vitro analysis of Ah receptor domains involved in ligand-activated DNA recognition
###end article-title 94
###begin article-title 95
Subunit composition of the heteromeric cytosolic aryl hydrocarbon receptor complex
###end article-title 95
###begin article-title 96
Recruitment of the NCoA/SRC-1/p160 family of transcriptional coactivators by the aryl hydrocarbon receptor/aryl hydrocarbon receptor nuclear translocator complex
###end article-title 96
###begin article-title 97
The aryl hydrocarbon receptor complex
###end article-title 97
###begin article-title 98
Differential recruitment of coactivator RIP140 by Ah and estrogen receptors. Absence of a role for LXXLL motifs
###end article-title 98
###begin article-title 99
Interactions of nuclear receptor coactivator/corepressor proteins with the aryl hydrocarbon receptor complex
###end article-title 99
###begin article-title 100
The silencing mediator of retinoic acid and thyroid hormone receptors can interact with the aryl hydrocarbon (Ah) receptor but fails to repress Ah receptor-dependent gene expression
###end article-title 100
###begin article-title 101
The Ah receptor: mediator of the toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds
###end article-title 101
###begin article-title 102
Transcriptional activation of heat shock protein 27 gene expression by 17beta-estradiol and modulation by antiestrogens and aryl hydrocarbon receptor agonists
###end article-title 102
###begin article-title 103
Flavonoids as aryl hydrocarbon receptor agonists/antagonists: effects of structure and cell context
###end article-title 103
###begin article-title 104
Genetic and molecular aspects of 2,3,7,8-tetrachlorodibenzo-p-dioxin action
###end article-title 104
###begin article-title 105
CYP1B1 represents the major PAH-responsive P450 cytochrome constitutively expressed in normal primary HMEC
###end article-title 105
###begin article-title 106
###xml 172 176 <span type="species:ncbi:10090">mice</span>
Genetic expression of aryl hydrocarbon hydroxylase activity: induction of monooxygenase activites and cytochrome P1-450 formation by 2,3,7,8-tetrachlorodibenzo-p-dioxin in mice genetically "nonresponsive" to other aromatic hydrocarbons
###end article-title 106
###begin article-title 107
###xml 31 37 <span type="species:ncbi:10090">murine</span>
Dioxin-dependent activation of murine Cyp1a-1 gene transcription requires protein kinase C-dependent phosphorylation
###end article-title 107
###begin article-title 108
Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas
###end article-title 108
###begin article-title 109
###xml 148 155 148 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
Aryl hydrocarbon receptor signaling plays a significant role in mediating benzo[a]pyrene- and cigarette smoke condensate-induced cytogenetic damage in vivo
###end article-title 109
###begin article-title 110
Aryl hydrocarbon receptor gene silencing with small inhibitory RNA differentially modulates Ah-responsiveness in MCF-7 and HepG2 cancer cells
###end article-title 110
###begin article-title 111
Aromatic hydrocarbon receptor interaction with the retinoblastoma protein potentiates repression of E2F-dependent transcription and cell cycle arrest
###end article-title 111
###begin article-title 112
Role of the aryl hydrocarbon receptor in cell cycle regulation
###end article-title 112
###begin article-title 113
A direct interaction between the aryl hydrocarbon receptor and retinoblastoma protein. Linking dioxin signaling to the cell cycle
###end article-title 113
###begin article-title 114
The aromatic hydrocarbon receptor modulates the Hepa 1c1c7 cell cycle and differentiated state independently of dioxin
###end article-title 114
###begin article-title 115
ER alpha-AHR-ARNT protein-protein interactions mediate estradiol-dependent transrepression of dioxin-inducible gene transcription
###end article-title 115
###begin article-title 116
Complementation of Ah receptor deficiency in hepatoma cells: negative feedback regulation and cell cycle control by the Ah receptor
###end article-title 116
###begin article-title 117
Modulation of oestrogen receptor signalling by association with the activated dioxin receptor
###end article-title 117
###begin article-title 118
Ligand activation of the aromatic hydrocarbon receptor transcription factor drives Bax-dependent apoptosis in developing fetal ovarian germ cells
###end article-title 118
###begin article-title 119
###xml 33 39 <span type="species:ncbi:10090">murine</span>
Differential susceptibilities of murine hepatoma 1c1c7 and Tao cells to the lysosomal photosensitizer NPe6: influence of aryl hydrocarbon receptor on lysosomal fragility and protease contents
###end article-title 119
###begin article-title 120
Molecular biology of the Ah receptor and its role in carcinogenesis
###end article-title 120
###begin article-title 121
The flavonoid galangin is an inhibitor of CYP 1A1 activity and an agonist of the AhR
###end article-title 121
###begin article-title 122
The case for expanded phytoestrogen research
###end article-title 122
###begin article-title 123
Regulatory interactions among three members of the vertebrate aryl hydrocarbon receptor family: AHR repressor, AHR1, and AHR2
###end article-title 123
###begin article-title 124
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc </italic>
###xml 78 83 <span type="species:ncbi:9606">human</span>
The aryl hydrocarbon receptor constitutively represses c-myc transcription in human mammary tumor cells
###end article-title 124
###begin article-title 125
Comparison of recombinant cell bioassays for the detection of Ah receptor agonists
###end article-title 125
###begin article-title 126
Peroxisome Proliferator-Activated Receptor g-Mediated NF-kB Activation and Apoptosis in Pre-B Cells
###end article-title 126
###begin article-title 127
Activation of the aryl hydrocarbon receptor/transcription factor and bone marrow stromal cell-dependent preB cell apoptosis
###end article-title 127
###begin article-title 128
###xml 79 83 79 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Kip1</sup>
###xml 92 97 92 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">WAF1 </sup>
Environmental chemical-induced pro/pre-B cell apoptosis: Analysis of c-Myc, p27Kip1, and p21WAF1 reveals a death pathway distinct from clonal deletion
###end article-title 128
###begin article-title 129
Possible involvement of aryl hydrocarbon receptor (AhR) in adult T-cell leukemia (ATL) leukemogenesis: constitutive activation of AhR in ATL
###end article-title 129
###begin article-title 130
Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer
###end article-title 130
###begin article-title 131
Characterization of the activated form of the aryl hydrocarbon receptor in the nucleus of HeLa cells in the absence of exogenous ligand
###end article-title 131
###begin article-title 132
###xml 90 95 <span type="species:ncbi:9606">human</span>
Comparative properties of the nuclear aryl hydrocarbon (Ah) receptor complex from several human cell lines
###end article-title 132
###begin article-title 133
Constitutive activation of the aromatic hydrocarbon receptor
###end article-title 133
###begin article-title 134
###xml 104 109 <span type="species:ncbi:9606">human</span>
Effect of transient expression of the oestrogen receptor on constitutive and inducible CYP1A1 in Hs578T human breast cancer cells
###end article-title 134
###begin article-title 135
a-Naphthoflavone acts as an antagonist of 2,3,7,8-tetrachlorodibenzo-p-dioxin by forming an inactive complex with the Ah receptor
###end article-title 135
###begin article-title 136
###xml 88 94 <span type="species:ncbi:10090">murine</span>
Induction of PreB cell apoptosis by 7,12-dimethylbenz[a]anthracene in long-term primary murine bone marrow cultures
###end article-title 136
###begin article-title 137
###xml 71 76 <span type="species:ncbi:9606">human</span>
Effect of tamoxifen and 2-methoxyestradiol alone and in combination on human breast cancer cell proliferation
###end article-title 137
###begin article-title 138
Mechanism of action and development of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers (Review)
###end article-title 138
###begin article-title 139
###xml 109 114 <span type="species:ncbi:9606">human</span>
Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling
###end article-title 139
###begin article-title 140
Identification of a novel mechanism of regulation of Ah (dioxin) receptor function
###end article-title 140
###begin article-title 141
Structure and expression of the Ah receptor repressor gene
###end article-title 141
###begin article-title 142
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human arylhydrocarbon receptor repressor (AHRR) gene: genomic structure and analysis of polymorphism in endometriosis
###end article-title 142
###begin article-title 143
###xml 161 164 <span type="species:ncbi:10116">rat</span>
Primary structure and inducibility by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) of aryl hydrocarbon receptor repressor in a TCDD-sensitive and a TCDD-resistant rat strain
###end article-title 143
###begin article-title 144
Regulation of the cyclin D3 promoter by E2F1
###end article-title 144
###begin article-title 145
A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapy
###end article-title 145
###begin article-title 146
Cyclin A in cell cycle control and cancer
###end article-title 146
###begin article-title 147
Cyclins and breast cancer
###end article-title 147
###begin article-title 148
###xml 26 34 <span type="species:ncbi:9606">patients</span>
Cyclin E and prognosis in patients with breast cancer
###end article-title 148
###begin article-title 149
Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer
###end article-title 149
###begin article-title 150
The aryl hydrocarbon receptor displaces p300 from E2F-dependent promoters and represses S-phase specific gene expression
###end article-title 150
###begin article-title 151
###xml 128 133 <span type="species:ncbi:9606">human</span>
Constitutive activation and environmental chemical induction of the aryl hydrocarbon receptor/transcription factor in activated human B lymphocytes
###end article-title 151
###begin article-title 152
Regulation of constitutive gene expression through interactions of Sp1 protein with the nuclear aryl hydrocarbon receptor complex
###end article-title 152
###begin article-title 153
###xml 132 137 <span type="species:ncbi:9606">human</span>
Overlapping but unique DNA binding specificites of the Ah receptor and constitutive dioxin-responsive element binding proteins from human keratinocytes
###end article-title 153
###begin article-title 154
Cytochrome P4501A1 promotes G1 phase cell cycle progression by controlling aryl hydrocarbon receptor activity
###end article-title 154
###begin article-title 155
###xml 70 74 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 85 100 <span type="species:ncbi:10090">transgenic mice</span>
Alternative mammary oncogenic pathways are induced by D-type cyclins; MMTV-cyclin D3 transgenic mice develop squamous cell carcinoma
###end article-title 155
###begin article-title 156
Differential expression of p16/p21/p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis, and tumour progression in invasive ductal carcinoma of the breast
###end article-title 156
###begin article-title 157
###xml 38 43 <span type="species:ncbi:9606">human</span>
Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-type cyclin-CDK complexes
###end article-title 157
###begin article-title 158
Cyclin D1 in breast cancer pathogenesis
###end article-title 158
###begin title 159
Figures and Tables
###end title 159
###begin p 160
Hs578T cells express nuclear aryl hydrocarbon receptor (AhR). Cytoplasmic and nuclear cell extracts prepared from subconfluent monolayers of malignant, estrogen receptor negative Hs578T cells were analyzed by western immunoblotting with AhR-specific antibody following SDS-PAGE. Blots were stripped and re-probed for lamin A/C and alpha-tubulin to confirm purity of the nuclear and cytoplasmic cell fractions, respectively. Representative data from a total of three experiments are shown.
###end p 160
###begin p 161
###xml 54 62 54 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGudLuc </italic>
###xml 182 190 181 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">phRL-TK </italic>
###xml 210 215 208 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGL3 </italic>
###xml 218 226 216 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGudLuc </italic>
###xml 261 264 259 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 269 272 267 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5 </sup>
###xml 286 289 284 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 294 297 292 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5 </sup>
###xml 329 332 327 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 373 377 363 367 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 388 392 378 382 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 406 409 396 399 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-9 </sup>
###xml 438 439 428 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 607 611 597 601 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 832 833 822 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 864 865 854 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 875 879 865 869 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 1100 1101 1090 1091 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1194 1201 1184 1191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGudLuc</italic>
Galangin inhibits aryl hydrocarbon receptor-dependent pGudLuc reporter activity. Hs578T cells were left untransfected or were transfected with 0.5 mug/well renilla luciferase vector phRL-TK and 0.1 mug control pGL3 or pGudLuc vector per well and treated with 10-4 to 10-5 M galangin, 10-4 to 10-5 M indole 3-carbinol (I3C), or 10-6 M alpha-naphthoflavone (alpha-NF) in the (a) absence or (b) presence of 10-9 M 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Cells were harvested 18 hours later and luciferase activity assayed. Firefly luciferase activity was normalized to renilla activity in each experiment. (a) Data pooled from 4 to 16 experiments are presented as the average fold increase relative to non-transfected cells + standard error. An asterisk (*) indicates a significant difference relative to vehicle-treated controls, p < 0.02. A cross (+) indicates p = 0.056. (b) Data pooled from 4 to 16 experiments are presented as the average fold increase relative to non-transfected cells + standard error. An asterisk (*) indicates a significant difference relative to vehicle-treated controls, p < 0.02. A hash sign (#) indicates a significant increase in activity relative to untreated, pGudLuc-transfected controls.
###end p 161
###begin p 162
###xml 119 122 119 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 127 130 127 130 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 144 147 144 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 152 155 152 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 187 189 187 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5</sup>
###xml 192 195 192 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 347 351 339 343 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 627 628 619 620 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 684 685 676 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 694 698 686 690 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 769 772 761 764 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 858 861 850 853 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
Galangin inhibits proliferation of Hs578T breast cancer cells. Hs578T cells were treated in triplicate with vehicle, 10-4 to 10-6 M galangin, 10-4 to 10-6 M indole 3-carbinol (I3C), or 10-5-10-6 M alpha-naphthoflavone (alpha-NF) and grown in 3H-thymidine-containing media for 18 hours. Triplicates were averaged for each point in each experiment. (a) Data are pooled from 3 to 11 experiments and presented as the percent of control (vehicle-treated) counts per minute (CPM) + standard error. In 11 experiments, the average CPM in vehicle-treated controls was 35,583 + 6,893. An asterisk (*) indicates a significant decrease in 3H-thymidine incorporation relative to vehicle controls, p < 0.05. (b) Data obtained with galangin as above were replotted to determine the IC50 (median inhibition concentration) (median inhibition concentration). The calculated IC50 was 11 muM.
###end p 162
###begin p 163
###xml 43 49 43 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FhAhRR</italic>
###xml 74 82 74 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGudLuc </italic>
###xml 202 210 201 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">phRL-TK </italic>
###xml 222 229 220 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGudLuc</italic>
###xml 273 278 270 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pcDNA</italic>
###xml 289 295 285 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FhAhRR</italic>
###xml 308 315 303 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FhAhRR </italic>
###xml 322 326 317 321 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 337 341 332 336 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 355 358 350 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-9 </sup>
###xml 387 388 382 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 775 776 770 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Aryl hydrocarbon receptor (AhR) repressor (FhAhRR) inhibits AhR-dependent pGudLuc reporter activity. Hs578T cells were left untransfected or were transfected with 0.5 mug/well renilla luciferase vector phRL-TK and 0.1 mug pGudLuc/well together with 0.5 mug control vector (pcDNA), 0.1 mug FhAhRR, or 0.5 mug FhAhRR in the (a) absence or (b) presence of 10-9 M 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Cells were harvested 18 hours later and luciferase activity assayed. Firefly luciferase activity was normalized to renilla activity in each experiment. Data pooled from six experiments are presented as the average fold increase relative to non-transfected cells + standard error. An asterisk (*) indicates a significant difference relative to pcDNA-transfected controls, p < 0.001.
###end p 163
###begin p 164
###xml 141 147 141 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pcDNA </italic>
###xml 162 169 162 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FhAhRR </italic>
###xml 284 285 284 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 350 351 350 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
Aryl hydrocarbon receptor repressor does not inhibit proliferation of Hs578T breast cancer cells. Hs578T cells were transfected with control pcDNA vector or with FhAhRR plasmid as in Figure 4, plated in triplicate in 96-well plates, and allowed to adhere overnight before addition of 3H-thymidine. Cells were harvested 18 hours later and assayed for 3H-thymidine incorporation. Triplicates were averaged in each experiment. Data are pooled from three experiments and are presented as the mean counts per minute (CPM) + standard error. There were no statistical differences between groups.
###end p 164
###begin p 165
###xml 74 75 74 75 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 77 79 77 79 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 208 211 208 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 216 219 216 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 239 241 239 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5</sup>
###xml 243 246 243 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 286 289 278 281 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 534 538 526 530 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 610 613 602 605 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 627 630 619 622 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5 </sup>
###xml 648 651 636 639 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 682 686 670 674 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 772 773 760 761 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 775 777 763 765 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 897 898 885 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 984 985 972 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Galangin and indole 3-carbinol (I3C) block Hs578T cells progression from G0/G1 into cell cycle. Hs578T cells were synchronized by serum deprivation for 48 h followed by rescue with 10% serum. As indicated, 10-4 to 10-6 M galangin (Gal), 10-5-0-6 M alpha-naphthoflavone (alpha-NF), or 10-4 M I3C were added to triplicate wells at the time of serum rescue. Cells were harvested 24 hours later and assayed for DNA content by propidium iodide (PI) staining and flow cytometry. Data from triplicate wells were averaged in each experiment. (a) Flow cytometry histograms from one representative experiment in which 10-4 M galangin, 10-5 M alpha-NF, and 10-4 M I3C were used are presented. (b) Data pooled from 4 to 9 experiments are presented as the mean percentage of cells in G0/G1 + standard error. An asterisk (*) indicates a significant increase relative to serum starved, vehicle treated cultures, p < 0.01. A cross (+) indicates a significant increase relative to untreated cultures, p < 0.01.
###end p 165
###begin p 166
###xml 125 128 125 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 148 151 148 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 183 186 183 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5 </sup>
###xml 410 414 399 403 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 503 507 492 496 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 919 920 902 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 976 977 959 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Galangin down-regulates expression of cyclins D3, A, and E. Hs578T cells were left untreated or were treated with vehicle, 10-4 M galangin, 2.5 x 10-4 M indole 3-carbinol (I3C), or 10-5 M alpha-naphthoflavone (alpha-NF) and assayed for cyclin D1, D3, E, and A expression 18 hours thereafter by western blotting. Blots were stripped and reprobed with beta-actin-specific antibody to control for sample loading. (a) Data from one representative experiment from a total of three experiments are presented. (b) Cyclin band densities were normalized with beta-actin band densities and then expressed as a percentage of beta-actin normalized cyclin expression in untreated cultures. Data are pooled from three experiments and expressed as the percent of control of the respective normalized band densities + standard errors. An asterisk (*) indicates a significant decrease in cyclin expression relative to vehicle controls, p < 0.001. A cross (+) indicates a significant decrease, p < 0.02.
###end p 166

